Short answer
Humacyte, Inc. (HUMA) filed an 8-K current report with the SEC on March 19, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure). Registered direct offering of 25 million shares of common stock at $0.80 per share, raising gross proceeds of $20 million.
Humacyte, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Registered direct offering of 25 million shares of common stock at $0.80 per share, raising gross proceeds of $20 million
- Net proceeds expected around $18.4 million after placement agent fees and expenses
- Offering facilitated by Titan Partners Group LLC acting as placement agent under a placement agreement
- Issued pursuant to effective shelf registration on Form S-3 filed September 2025, permitting fast capital raising
- Proceeds to provide liquidity for growth initiatives or operational needs, diluting existing shareholders by ~9.5% assuming 262 million shares outstanding
Item 7.01 · Regulation FD Disclosure
- Disclosure clarifies 7.01 filing not “filed” under Exchange Act Section 18 liability provisions
- Information not incorporated by reference in future Securities Act or Exchange Act filings
- Limits legal exposure for Humacyte regarding forward-looking or unvetted disclosures in this item
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Humacyte, Inc. 8-K filings
Get the next HUMA 8-K as it lands
Follow HUMA for push alerts, or ask the research agent what this filing means.